Exploring novel fluorine-rich fuberidazole derivatives as hypoxic cancer inhibitors: Design, synthesis, pharmacokinetics, molecular docking, and DFT evaluations - Muhammad Babar Taj; Ahmad Raheel; Rabia Ayub; Afnan M. Alnajeebi; Matokah M. Abualnaja; Alaa Hamed Habib; Walla Alelwani; Sadia Noor; Sami Ullah; Abdullah G. Al‐Sehemi; Rahime Şimşek; Nouf A. Babteen; et al. (PLOS ONE, 2023)